Bogart Wealth LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 42.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,389 shares of the company’s stock after buying an additional 6,998 shares during the period. Merck & Co., Inc. makes up about 1.0% of Bogart Wealth LLC’s holdings, making the stock its 24th biggest holding. Bogart Wealth LLC’s holdings in Merck & Co., Inc. were worth $1,499,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in MRK. Stelac Advisory Services LLC purchased a new stake in Merck & Co., Inc. during the 2nd quarter worth $104,000. Perennial Advisors LLC boosted its position in Merck & Co., Inc. by 10.7% during the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock worth $104,000 after purchasing an additional 157 shares during the period. Cascade Investment Advisors Inc. boosted its position in Merck & Co., Inc. by 15.5% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after purchasing an additional 232 shares during the period. Solaris Asset Management LLC boosted its position in Merck & Co., Inc. by 6.3% during the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock worth $124,000 after purchasing an additional 115 shares during the period. Finally, Harbour Capital Advisors LLC purchased a new stake in Merck & Co., Inc. during the 1st quarter worth $127,000. Institutional investors and hedge funds own 73.84% of the company’s stock.
A number of brokerages recently weighed in on MRK. BMO Capital Markets set a $68.00 price target on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Wednesday. TheStreet cut shares of Merck & Co., Inc. from a “b” rating to a “c” rating in a research report on Monday, November 27th. Bank of America began coverage on shares of Merck & Co., Inc. in a research report on Tuesday, November 28th. They issued a “buy” rating and a $64.00 price objective for the company. Deutsche Bank decreased their price objective on shares of Merck & Co., Inc. from $62.00 to $59.00 and set a “hold” rating for the company in a research report on Friday, November 24th. Finally, Sanford C. Bernstein reissued a “buy” rating and issued a $64.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $66.29.
Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.08. The business had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. Merck & Co., Inc. had a net margin of 11.60% and a return on equity of 27.08%. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.07 EPS. analysts predict that Merck & Co., Inc. will post 3.95 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, January 8th. Stockholders of record on Friday, December 15th will be paid a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date is Thursday, December 14th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.47. Merck & Co., Inc.’s dividend payout ratio is 114.97%.
Merck & Co., Inc. announced that its Board of Directors has initiated a share repurchase plan on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.
In other news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.25% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/12/17/merck-co-inc-mrk-shares-bought-by-bogart-wealth-llc.html.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.